Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03056703 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT03056703 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 38 participants.
The verdict
NCT03056703, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The primary objective of this study is to compare the bioavailability of a single dose of a new 1000 mg fast release ASA (acetylsalicylic acid) tablet with that of two tablets of a commercially available 500 mg fast release tablet and to test for bioequivalence of the new versus the commercial product in healthy adult subjects.
Interventions
- DRUG Acetylsalicylic acid (Aspirin, BAY1019036)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03056703
The ClinicalTrials.gov registry entry for NCT03056703 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetylsalicylic acid (Aspirin, BAY1019036) is the first listed.
NCT03056703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03056703 about?
NCT03056703 is a clinical study titled "Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets". The primary objective of this study is to compare the bioavailability of a single dose of a new 1000 mg fast release ASA (acetylsalicylic acid) tablet with that of two tablets of a commercially available 500 mg fast release tablet and to test for bioequivalence of the new versus the commercial produ...
What is the current status of trial NCT03056703?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2014-02. Estimated completion is 2014-03.
What interventions are being tested in trial NCT03056703?
The interventions under investigation include: Acetylsalicylic acid (Aspirin, BAY1019036) (DRUG).
Who is sponsoring clinical trial NCT03056703?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.